Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Steve Fancy who wrote (3116)	12/3/1997 6:33:00 PM
From: lrb	Read Replies (1) of 6136

A couple of questions for someone familiar with this industry (Rick Harmon, are you there?): First, should we assume that Roche knows everything that Agouron knows about AG3340? That is, if Agouron wants to persue it and Roche does not, must that just reflect different judgements of its potential based on the same set of facts? Second, if AG3340 is successfully brought to market, how will it be used? My naive understanding is that if it works, it will prevent metastasis of tumors, but will not kill the tumor. So I would think that this would only be used in situations where all methods of getting rid of the tumor (surgery, chemotherapy, radiation) had been ruled out. Obviously I don't know much about this. Maybe one of the MD's on this thread can comment?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next